Indeed, activation of the AKT survival pathway was demonstrated to contribute to TRAIL resistance and the PI3K inhibitor LY294002, or knockdown of AKT, sensitised resistant cancer cells to TRAIL [94]. This evidence concerns the gene AKT1 and cancer.